RECEIVED CENTRAL FAX CENTER

AUG 2 3 2006

Attorney Docket No.: 6012.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Shiro Fukuyama

Confirmation No: 5914

Serial No.: 10/618,976

Group Art Unit: 1652

Filed: July 14, 2003

Examiner: Rao

For: Polypeptides Having Glucanotransferase Activity And Nucleic Acids Encoding Same

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Amendment Fee Transmittal (in duplicate)
- 2. Amendment
- 3. Statement under 37 C.F.R. 1.808

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Rao, fax number 571-273-8300.

Respectfully submitted,

Date: August 23, 2006

Lourdes Ayala

Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600

New York, NY 10110 (212) 840-0097

RECEIVED CENTRAL FAX CENTER

AUG 2 3 2008

Attorney Docket No.: 6012,210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Shiro Fukuyama

Confirmation No: 5914

Serial No.: 10/618,976

Group Art Unit: 1652

Filed: July 14, 2003

Examiner: Rao

For: Polypeptides Having Glucanotransferase Activity And Nucleic Acids Encoding Same

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir.

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed March 15, 2006.

It is respectfully requested that the time for response to the Office Action be extended for a period of 3 months from June 15, 2006 to September 15, 2006. The required fee for the extension is estimated to be \$1,020.

No additional claims fee is required. Please charge the required extension and claims fees, estimated to be \$1,020, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: August 23, 2006

Jasop I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (212) 840-0097

AUG 2 3 2006

Attorney Docket No.: 6012.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Shiro Fukuyama

Confirmation No: 5914

Serial No.: 10/618,976

Group Art Unit: 1652

Filed: July 14, 2003

Examiner: Rao

STATEMENT UNDER 37 C.F.R. 1.808

For: Polypeptides Having Glucanotransferase Activity And Nucleic Acids Encoding Same

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The above-captioned application refers to deposit(s) of biological material which have been made at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM) under the Budapest Treaty and assigned accession number DSM 13049.

All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the U.S. patent.

The deposit(s) will be maintained for (a) thirty years, (b) at least five years after the most recent request for the furnishing of a sample of the deposit is received by the depository, or (c) the enforceable life of the U.S. patent granted from this application, whichever is longest. If the deposited material becomes inviable during the above term, the deposited material will be replaced.

Respectfully submitted,

Date: August 23, 2006

Jasop 1. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212) 840-0097